Comparing Direct vs Indirect Methods for Cascade Screening

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Maryland, Baltimore

About this trial

An important aspect of successful genomic medicine implementation is developing effective approaches for screening at-risk family members after probands are identified, also known as cascade screening. Most cascade screening studies conducted to date have been conducted outside the US, and very few studies have used a rigorous approach involving a comparator group or randomized controlled design. A major question in the field is how to most effectively implement cascade screening, given commonly cited communication barriers, while respecting privacy among probands and family members. This study will conduct a randomized controlled trial to assess direct contact of relatives by study team members vs indirect, or proband-initiated, contact. We will assess efficacy of the cascade screening intervention, patient-centered outcomes regarding mental, physical, and psychosocial outcomes in probands and family members, and implementation evaluation outcomes.

Individuals who are known to carry the KCNQ1 Met224Thr or APOB Arg3527Gln variant will be eligible to participate. After providing consent and being deemed eligible, individuals will be randomized in a 1:1 manner into the direct or indirect contact of family members arm of the study. The randomization will be stratified by variant to ensure equal representation of each variant in the study arms. Individuals in the indirect arm will be instructed to contact their first-degree family members about the opportunity to be screened. They will be provided with a disease-specific pamphlet and a family letter explaining the cascade screening. In the direct arm, probands will be advised that the study staff will be contacting their family members. They will be instructed to also contact their family members prior to the study team contacting them. Approximately two weeks after this meeting with the proband, the study staff will mail letters to eligible first-degree family members of the probands. If we do not hear back from individual family members, we will follow-up with another letter, telephone call, or home visit. The information contained in the letters will be the same information for both the direct and indirect arms of the study. All interested family members will receive pre-test counseling and free, in-home, saliva-based genetic testing, and post-test counseling.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

KCNQ1 Thr224Met or APOB R3527Q carrier

18 years or older

Disqualifiers

None

1st degree relative of a KCNQ1 Thr224Met or APOB Arg3527Gln carrier

None

Trial design

Design model

Single group

Treatments tested in this trial

  • Direct contact of family members for cascade screening of relevant variants

    Behavioral

    Study team members will directly contact potentially impacted family members to offer genetic testing of relevant variant.

Treatment groups

200 Participants
are divided into 2 treatment groups
Group A: Direct contactExperimental treatment 1 intervention
Group B: Indirect contactNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Uptake of cascade screening among all first-degree relatives

Proportion of first-degree relatives who undergo testing/All eligible first-degree relatives

Time frame
Through study completion: approximately 4 years

Secondary outcomes

1

Number of new cases detected among all first-degree family members

New cases/All eligible first-degree family members

Time frame
Through study completion: approximately 4 years
2

Perceived alignment of ethical principles questionnaire

Among probands and family members

Time frame
up to 6 months
3

Anxiety regarding method of contact questionnaire

Among probands and family members

Time frame
up to 6 months
4

Perceived pressure to undergo testing/share health information questionnaire

Among probands and family members

Time frame
up to 6 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.